



Medicines & Healthcare products
Regulatory Agency

MHRA Central Freedom of
Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

[MHRA Website](#)

Our Ref: **FOI2025/00316**

25 April 2025

Dear [REDACTED],

Thank you for your Freedom of Information (Fol) request received on 26 March. You wrote:

Could you please share full latest WDA (GDP) & MS/GMP/MIA inspection report:

*(1) ACTIVE PHARMA SUPPLIES LIMITED, UNIT 2, FORWARD INDUSTRIAL ESTATE,
TALBOT ROAD, LEYLAND, PR25 2ZJ, UNITED KINGDOM*

*(2) ARC PHARMA (UK) LIMITED , UNIT 3, CURO PARK, FROGMORE, ST. ALBANS,
AL2 2DD, UNITED KINGDOM*

*(3) SYRI LIMITED, UNIT 4, BRADFIELD ROAD, RUISLIP, HA4 0NU, UNITED
KINGDOM*

*(4) VALNEVA SCOTLAND LIMITED, 1 OAKBANK PARK PLACE, MID CALDER,
LIVINGSTON, EH53 0TN, UNITED KINGDOM*

*(5) HAMOL LIMITED, NOTTINGHAM SITE, THANE ROAD, NOTTINGHAM, NG90 2DB,
UNITED KINGDOM*

MHRA Response

Please find the Inspection Reports for Active Pharma Supplies Limited, Arc Pharma (UK) Limited, Syri Limited and Hamol Limited attached.

You will see that some information has been redacted. The relevant sections of the Freedom of Information Act are:

Section 40:

This information contains elements of personal data, the disclosure of which would be unfair in that it would breach the first principle of the Data Protection Act which says that information must be processed fairly and lawfully.

Section 43(2):

Release of all, or part of, the information would, or would be likely to, cause harm to the third party's commercial interests.

We have considered the balance of the public interest when applying this exemption. The exemption is to safeguard the commercially sensitive information / industrial secrets of a third party / commercial enterprise (which can include a Government Department). This exemption is conditional on the public interest in releasing it not outweighing the company's/commercial enterprise's right to confidentiality and the probable damage that the company/commercial enterprise could suffer as a result of the information being released. In

this case we have not identified any issues which would benefit the public as a whole by being brought to their attention (examples of issues would be a major public health risk or a major procedural failure or irregularity)

The latest inspection report Valneva Scotland Limited has not yet been finalised by the inspector. Until finalised, we consider inspection reports to be commercially sensitive, and s43(2) applies.

Please note that the inspection report for Hamol Limited references Reckitt Benckiser Healthcare International Limited. Hamol Limited is not referenced in the report but the site inspector has confirmed they are the same site and the inspection covered the relevant functions.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>